{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T21:08:03Z","timestamp":1774559283768,"version":"3.50.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["HealthLumen"],"award-info":[{"award-number":["HealthLumen"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12325-024-02863-4","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T07:05:00Z","timestamp":1724137500000},"page":"3905-3921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inside ANEMIA of CKD: Projecting the Future Burden of Anemia of Chronic Kidney Disease and Benefits of Proactive Management: A Microsimulation Model of the Chinese Population"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6689-3599","authenticated-orcid":false,"given":"Lise","family":"Retat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dunming","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8976-1919","authenticated-orcid":false,"given":"Laura","family":"Webber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4863-3961","authenticated-orcid":false,"given":"Alexander","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Card-Gowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chalet","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6546-7769","authenticated-orcid":false,"given":"Juan Jose","family":"Garcia Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2778-1604","authenticated-orcid":false,"given":"Claudia","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Grandy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"2863_CR1","unstructured":"KDIGO 2012. Clinical practice guideline for the evaluation and management of chronic kidney disease. https:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/KDIGO_2012_CKD_GL.pdf. Accessed 20 Feb 2023."},{"key":"2863_CR2","doi-asserted-by":"crossref","unstructured":"Mennini FS, Cabrera C, Card-Gowers J, et al. Inside CKD: projecting the economic burden of chronic kidney disease using patient-level microsimulation modelling. [Poster] 2021. https:\/\/www.healthlumen.com\/wp-content\/uploads\/2022\/06\/posb68-inside-ckdispor-eucost-burdenposterrevised-submission-pdf.pdf. Accessed 22 Apr 2024.","DOI":"10.1016\/j.jval.2021.11.341"},{"key":"2863_CR3","doi-asserted-by":"crossref","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709\u201333.","DOI":"10.1016\/S0140-6736(19)32977-0"},{"issue":"7","key":"2863_CR4","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1093\/ndt\/gfs095","volume":"27","author":"A Chang","year":"2012","unstructured":"Chang A, Kramer H. CKD progression: a risky business. Nephrol Dial Transpl. 2012;27(7):2607\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"21","key":"2863_CR5","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1001\/2013.jamainternmed.85","volume":"172","author":"A Vivante","year":"2012","unstructured":"Vivante A, Golan E, Tzur D, et al. Body mass index in 1.2\u00a0million adolescents and risk for end-stage renal disease. Arch Intern Med. 2012;172(21):1644\u201350.","journal-title":"Arch Intern Med"},{"issue":"1","key":"2863_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","volume":"74","author":"E Ku","year":"2019","unstructured":"Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74(1):120\u201331.","journal-title":"Am J Kidney Dis"},{"key":"2863_CR7","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","volume":"40","author":"V Jha","year":"2023","unstructured":"Jha V, Al-Ghamdi SMG, Li G, et al. Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD research programme. Adv Ther. 2023;40:4405.","journal-title":"Adv Ther"},{"issue":"2","key":"2863_CR8","first-page":"171","volume":"11","author":"L Chen","year":"2023","unstructured":"Chen L, Cheng J, Qiu T, et al. Clinical research progress on xenogeneic kidney transplantation. Pract J Organ Transpl (Electronic Version). 2023;11(2):171\u20134.","journal-title":"Pract J Organ Transpl (Electronic Version)"},{"issue":"3","key":"2863_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.kint.2018.11.011","volume":"95","author":"F Wang","year":"2019","unstructured":"Wang F, Yang C, Long J, et al. Executive summary for the 2015 Annual Data Report of the China Kidney Disease Network (CK-NET). Kidney Int. 2019;95(3):501\u20135.","journal-title":"Kidney Int"},{"key":"2863_CR10","unstructured":"KDIGO. KDIGO Clinical practice guideline for anemia in chronic kidney disease. https:\/\/kdigo.org\/wp-content\/uploads\/2016\/10\/KDIGO-2012-Anemia-Guideline-English.pdf Accessed 20 Feb 2023. 2012."},{"issue":"24","key":"2863_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003872","volume":"95","author":"Y Li","year":"2016","unstructured":"Li Y, Shi H, Wang WM, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study. Medicine (Baltimore). 2016;95(24):e3872.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2863_CR12","first-page":"562","volume":"36","author":"P Lin","year":"2009","unstructured":"Lin P, Ding X-Q, Yuan M, Liu H. A cross-sectional study on anemia and its risk factors in chronic kidney disease. Fudan Univ J Med Sci. 2009;36(5):562\u20135.","journal-title":"Fudan Univ J Med Sci"},{"issue":"1","key":"2863_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12882-021-02247-8","volume":"22","author":"Y Shen","year":"2021","unstructured":"Shen Y, Wang J, Yuan J, et al. Anemia among Chinese patients with chronic kidney disease and its association with quality of life\u2014results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol. 2021;22(1):64.","journal-title":"BMC Nephrol"},{"issue":"1","key":"2863_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12882-016-0312-9","volume":"17","author":"D Eriksson","year":"2016","unstructured":"Eriksson D, Goldsmith D, Teitsson S, Jackson J, van Nooten F. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol. 2016;17(1):97.","journal-title":"BMC Nephrol"},{"issue":"5","key":"2863_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1053\/j.jrn.2019.11.003","volume":"30","author":"J Hoshino","year":"2020","unstructured":"Hoshino J, Muenz D, Zee J, et al. Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with stage\u00a03\u20135 nondialysis CKD. J Ren Nutr. 2020;30(5):404\u201314.","journal-title":"J Ren Nutr"},{"issue":"1","key":"2863_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12882-020-01746-4","volume":"21","author":"H van Haalen","year":"2020","unstructured":"van Haalen H, Jackson J, Spinowitz B, Milligan G, Moon R. Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrol. 2020;21(1):88.","journal-title":"BMC Nephrol"},{"issue":"1","key":"2863_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.15586\/jrenhep.2017.5","volume":"1","author":"AR Krishnan","year":"2017","unstructured":"Krishnan AR, Trinder D, Chua ACG, Chakera A, Ramm GA, Olynyk J. Anaemia of chronic kidney disease: what we know now. J Renal Hepat Disord. 2017;1(1):11\u20139.","journal-title":"J Renal Hepat Disord"},{"issue":"1","key":"2863_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41100-017-0114-y","volume":"3","author":"H Yamamoto","year":"2017","unstructured":"Yamamoto H, Nishi S, Tomo T, et al. 2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ren Replace Ther. 2017;3(1):1\u201346.","journal-title":"Ren Replace Ther"},{"issue":"2","key":"2863_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000213166","volume":"32","author":"J Wish","year":"2009","unstructured":"Wish J, Schulman K, Law A, Nassar G. Healthcare expenditure and resource utilization in patients with anaemia and chronic kidney disease: a retrospective claims database analysis. Kidney Blood Press Res. 2009;32(2):110\u20138.","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"2863_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s41669-019-0132-5","volume":"3","author":"PE Pergola","year":"2019","unstructured":"Pergola PE, Pecoits-Filho R, Winkelmayer WC, et al. Economic burden and health-related quality of life associated with current treatments for anaemia in patients with CKD not on dialysis: a systematic review. Pharmacoecon Open. 2019;3(4):463\u201378.","journal-title":"Pharmacoecon Open"},{"issue":"4","key":"2863_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1517\/14656566.2012.658369","volume":"13","author":"F Locatelli","year":"2012","unstructured":"Locatelli F, Del Vecchio L. An expert opinion on the current treatment of anemia in patients with kidney disease. Expert Opin Pharmacother. 2012;13(4):495\u2013503.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"2863_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0002-9343(00)00396-X","volume":"109","author":"JC Barton","year":"2000","unstructured":"Barton JC, Barton EH, Bertoli LF, Gothard CH, Sherrer JS. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med. 2000;109(1):27\u201332.","journal-title":"Am J Med"},{"issue":"2","key":"2863_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1634\/theoncologist.12-2-231","volume":"12","author":"DH Henry","year":"2007","unstructured":"Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12(2):231\u201342.","journal-title":"Oncologist"},{"issue":"2","key":"2863_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/ijms19020389","volume":"19","author":"JM Kaplan","year":"2018","unstructured":"Kaplan JM, Sharma N, Dikdan S. Hypoxia-inducible factor and its role in the management of anemia in chronic kidney disease. Int J Mol Sci. 2018;19(2):389.","journal-title":"Int J Mol Sci"},{"key":"2863_CR25","unstructured":"FDA. FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-modified-dosing-recommendations-improve-safe-use-erythropoiesis. Accessed 20 Feb 2023. 2017."},{"issue":"12","key":"2863_CR26","first-page":"CD010590","volume":"2014","author":"SC Palmer","year":"2014","unstructured":"Palmer SC, Saglimbene V, Mavridis D, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014;2014(12):CD010590.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"2863_CR27","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.ekir.2021.05.020","volume":"6","author":"OM Guti\u00e9rrez","year":"2021","unstructured":"Guti\u00e9rrez OM. Treatment of iron deficiency anemia in CKD and end-stage kidney disease. Kidney Int Rep. 2021;6(9):2261\u20139.","journal-title":"Kidney Int Rep"},{"issue":"5","key":"2863_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/01.tp.0000437435.19980.8f","volume":"97","author":"MS Leffell","year":"2014","unstructured":"Leffell MS, Kim D, Vega RM, et al. Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation. Transplantation. 2014;97(5):525\u201333.","journal-title":"Transplantation"},{"issue":"1","key":"2863_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12882-018-0861-1","volume":"19","author":"WL St Peter","year":"2018","unstructured":"St Peter WL, Guo H, Kabadi S, et al. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. BMC Nephrol. 2018;19(1):67.","journal-title":"BMC Nephrol"},{"key":"2863_CR30","doi-asserted-by":"crossref","unstructured":"Chinese Experts Group of the Guideline for the Management of \u2018CKD-PeriDialysis\u2019, Chinese Non-government Medical Institutions Association. Chinese clinical practice guideline for the management of \u201cCKD-PeriDialysis\u201d\u2014the periods prior to and in the early-stage of initial dialysis. Kidney Int Rep. 2022;7(12 Suppl):S531\u2013S58.","DOI":"10.1016\/j.ekir.2022.10.001"},{"issue":"7","key":"2863_CR31","first-page":"1046","volume":"44","author":"YF Chai","year":"2023","unstructured":"Chai YF, Lin HB, Ding GH, et al. Prevalence and treatment of anemia in chronic kidney disease patients based on regional medical big data. Zhonghua Liu Xing Bing Xue Za Zhi. 2023;44(7):1046\u201353.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"2863_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJNRD.S291393","volume":"14","author":"CM Hao","year":"2021","unstructured":"Hao CM, Wittbrodt ET, Palaka E, Guzman N, Dunn A, Grandy S. Understanding patient perspectives and awareness of the impact and treatment of anemia with chronic kidney disease: a patient survey in China. Int J Nephrol Renovasc Dis. 2021;14:53\u201364.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2863_CR33","unstructured":"Nephrology Physicians Branch of Chinese Medical Doctor Association Nephrology Guidelines Working Group. Clinical practice guidelines for the diagnosis and treatment of renal anemia in China. Chin Med J. 2021;101:1463\u2013502."},{"issue":"1","key":"2863_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","volume":"11","author":"VH Haase","year":"2021","unstructured":"Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl. 2021;11(1):8\u201325.","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"2863_CR35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14737167.2020.1747436","volume":"20","author":"Z Hu","year":"2020","unstructured":"Hu Z, Tao H, Shi A, Pan J. The efficacy and economic evaluation of roxadustat treatment for anemia in patients with kidney disease not receiving dialysis. Expert Rev Pharmacoecon Outcomes Res. 2020;20(4):411\u20138.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"2863_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12325-022-02353-5","volume":"40","author":"N Tangri","year":"2023","unstructured":"Tangri N, Chadban S, Cabrera C, Retat L, S\u00e1nchez JJG. Projecting the epidemiological and economic impact of chronic kidney disease using patient-level microsimulation modelling: rationale and methods of inside CKD. Adv Ther. 2023;40(1):265\u201381.","journal-title":"Adv Ther"},{"key":"2863_CR37","unstructured":"Retat L, Webber L, Garcia Sanchez JJ, et al. Quantifying the epidemiological burden of anemia of CKD in the USA and Canada via microsimulation modelling. 2021. https:\/\/www.healthlumen.com\/wp-content\/uploads\/2022\/04\/NKF-Inside-ANEMIA-of-CKD-EPI-burden-US-and-CANADA.pdf. Accessed 22 Apr 2024."},{"key":"2863_CR38","unstructured":"Garcia Sanchez JJ, et al. Inside Anemia of CKD: Quantifying the epidemiological burden of anemia of CKD in Canada via microsimulation modelling. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2468024921004824#:~:text=Inside%20ANEMIA%20of%20CKD%20is,disease%20will%20increase%20in%20parallel. Accessed Dec 2023."},{"key":"2863_CR39","unstructured":"United Nations. UN World Population Prospects data. https:\/\/population.un.org\/wpp\/. Accessed 21 Feb 2023."},{"issue":"9818","key":"2863_CR40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(12)60033-6","volume":"379","author":"L Zhang","year":"2012","unstructured":"Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815\u201322.","journal-title":"Lancet"},{"key":"2863_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.642296","volume":"8","author":"J Portol\u00e9s","year":"2021","unstructured":"Portol\u00e9s J, Mart\u00edn L, Broseta JJ, Cases A. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med (Lausanne). 2021;8:642296.","journal-title":"Front Med (Lausanne)"},{"key":"2863_CR42","unstructured":"World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva: World Health Organization; 2011 2011. Contract No.: WHO\/NMH\/NHD\/MNM\/11.1."},{"key":"2863_CR43","unstructured":"\u56fd\u5bb6\u80be\u810f\u75c5\u533b\u7597\u8d28\u91cf\u63a7\u5236\u4e2d\u5fc3 [Internet]. http:\/\/www.cnrds.net\/TxLogin. Accessed 22 Feb 2023."},{"issue":"1","key":"2863_CR44","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.kisu.2018.11.001","volume":"9","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhao MH, Zuo L, et al. China Kidney Disease Network (CK-NET) 2015 annual data report. Kidney Int Suppl (2011). 2019;9(1):e1\u201381.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"1","key":"2863_CR45","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12913-017-2190-7","volume":"17","author":"W Xue","year":"2017","unstructured":"Xue W, Tian P, Xiang H, et al. Outcomes for primary kidney transplantation from donation after citizens\u2019 death in China: a single center experience of 367 cases. BMC Health Serv Res. 2017;17(1):250.","journal-title":"BMC Health Serv Res"},{"key":"2863_CR46","unstructured":"Yin H, Yusheng Y. [Peritoneal dialysis opportunity and challenge]. http:\/\/qikan.cqvip.com\/Qikan\/Article\/Detail?id=664763526. Accessed 22 Feb 2022."},{"issue":"Suppl 1","key":"2863_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/1744-9987.12293","volume":"19","author":"Y Watanabe","year":"2015","unstructured":"Watanabe Y, Yamagata K, Nishi S, et al. Japanese society for dialysis therapy clinical guideline for \u201chemodialysis initiation for maintenance hemodialysis.\u201d Ther Apher Dial. 2015;19(Suppl 1):93\u2013107.","journal-title":"Ther Apher Dial"},{"issue":"6","key":"2863_CR48","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.kint.2020.09.003","volume":"98","author":"C Yang","year":"2020","unstructured":"Yang C, Gao B, Zhao X, et al. Executive summary for China Kidney Disease Network (CK-NET) 2016 annual data report. Kidney Int. 2020;98(6):1419\u201323.","journal-title":"Kidney Int"},{"issue":"13","key":"2863_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5414\/CNP86S104","volume":"86","author":"L Zhang","year":"2016","unstructured":"Zhang L, Zuo L. Current burden of end-stage kidney disease and its future trend in China. Clin Nephrol. 2016;86(13):27\u20138.","journal-title":"Clin Nephrol"},{"key":"2863_CR50","unstructured":"NHS Digital. Health Survey for England, 2016. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/health-survey-for-england\/health-survey-for-england-2016. Accessed 22 Feb 2023."},{"issue":"11","key":"2863_CR51","first-page":"1000","volume":"29","author":"XQ Sun","year":"2009","unstructured":"Sun XQ, Li JS, Lang YJ, et al. Investigation of epidemiologic features and treatment of chronic heart failure in some rural parts of Liaoning province. Chin J Pract Intern Med. 2009;29(11):1000\u20132.","journal-title":"Chin J Pract Intern Med"},{"key":"2863_CR52","unstructured":"Institute for Health Metrics and Evaluation. Global burden of disease. http:\/\/www.healthdata.org\/ Accessed 22 Feb 2023."},{"issue":"7","key":"2863_CR53","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/ndt\/gfv009","volume":"30","author":"P Masson","year":"2015","unstructured":"Masson P, Webster AC, Hong M, Turner R, Lindley RI, Craig JC. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrol Dial Transpl. 2015;30(7):1162\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"2863_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.12659\/AOT.883217","volume":"17","author":"W Zhao","year":"2012","unstructured":"Zhao W, Zhang L, Han S, et al. Cost analysis of living donor kidney transplantation in China: a single-center experience. Ann Transpl. 2012;17(2):5\u201310.","journal-title":"Ann Transpl"},{"issue":"5","key":"2863_CR55","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/13696998.2017.1297309","volume":"20","author":"J Huang","year":"2017","unstructured":"Huang J, Yin H, Zhang M, Ni Q, Xuan J. Understanding the economic burden of heart failure in China: impact on disease management and resource utilization. J Med Econ. 2017;20(5):549\u201353.","journal-title":"J Med Econ"},{"issue":"3","key":"2863_CR56","doi-asserted-by":"publisher","first-page":"322","DOI":"10.11847\/zgggws2013-29-03-05","volume":"29","author":"LIU Yuan-yuan","year":"2013","unstructured":"Yuan-yuan LIU, Jun MA, Chang-ping LI. Hospitalization expense and its influencing factors among myocardial infarction patients. China Public Heal. 2013;29(3):322\u201324. https:\/\/doi.org\/10.11847\/zgggws2013-29-03-05.","journal-title":"China Public Heal"},{"issue":"3","key":"2863_CR57","first-page":"277","volume":"11","author":"D Zhu","year":"2022","unstructured":"Zhu D, Shi X, Nicholas S, et al. Medical service utilization and direct medical cost of stroke in urban China. Int J Health Policy Manag. 2022;11(3):277\u201386.","journal-title":"Int J Health Policy Manag"},{"key":"2863_CR58","unstructured":"Zheng X, Zhang JCL. Disease composition and medical expenses of chronic kidney disease in People\u2019s Hospital of Xinjiang uygur autonomous region from 2012 to 2017: a cross-sectional survey. Chin J Evid Based Med. 2018;18(9)."},{"issue":"7","key":"2863_CR59","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s11121-015-0610-7","volume":"17","author":"KG Hill","year":"2016","unstructured":"Hill KG, Woodward D, Woelfel T, Hawkins JD, Green S. Planning for long-term follow-up: strategies learned from longitudinal studies. Prev Sci. 2016;17(7):806\u201318.","journal-title":"Prev Sci"},{"key":"2863_CR60","doi-asserted-by":"crossref","unstructured":"Peng W, Chen S, Chen X, et al. Trends in major non-communicable diseases and related risk factors in China 2002\u20132019: an analysis of nationally representative survey data. Lancet Region Health Western Pac. 2023;43:100809.","DOI":"10.1016\/j.lanwpc.2023.100809"},{"key":"2863_CR61","first-page":"100630","volume":"33","author":"J Quan","year":"2023","unstructured":"Quan J, Zhao Z, Wang L, et al. Potential health and economic impact associated with achieving risk factor control in Chinese adults with diabetes: a\u00a0microsimulation modelling study. Lancet Regional Health Western Pac. 2023;33:100630.","journal-title":"Lancet Regional Health Western Pac"},{"issue":"15","key":"2863_CR62","doi-asserted-by":"publisher","first-page":"9761","DOI":"10.3390\/ijerph19159761","volume":"19","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Guo H, Zhang W, et al. Gaps and directions in addressing non-communicable and chronic diseases in China: a policy analysis. Int J Environ Res Public Health. 2022;19(15):9761.","journal-title":"Int J Environ Res Public Health"},{"key":"2863_CR63","doi-asserted-by":"crossref","unstructured":"Garcia Sanchez JJ, Xu M, Sorstadius E, et al. Estimating the Burden of Chronic Kidney Disease (CKD) in the UK: comparison of two health economic analysis methods. Nephrol Dial Transpl. 2020;35(Suppl 3).","DOI":"10.1093\/ndt\/gfaa142.P0773"},{"key":"2863_CR64","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.vhri.2017.04.001","volume":"12","author":"X Tan","year":"2017","unstructured":"Tan X, Liu X, Shao H. Healthy China 2030: a vision for health care. Value Health Reg Issues. 2017;12:112\u20134.","journal-title":"Value Health Reg Issues"},{"issue":"4","key":"2863_CR65","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/tobaccocontrol-2018-054372","volume":"28","author":"M Goodchild","year":"2019","unstructured":"Goodchild M, Zheng R. Tobacco control and Healthy China 2030. Tob Control. 2019;28(4):409\u201313.","journal-title":"Tob Control"},{"issue":"4","key":"2863_CR66","doi-asserted-by":"publisher","first-page":"78","DOI":"10.46234\/ccdcw2021.018","volume":"3","author":"Z Jiang","year":"2021","unstructured":"Jiang Z, Jiang W. Health education in the healthy China initiative 2019\u20132030. China CDC Wkly. 2021;3(4):78\u201380.","journal-title":"China CDC Wkly"},{"issue":"16","key":"2863_CR67","doi-asserted-by":"publisher","first-page":"346","DOI":"10.46234\/ccdcw2021.092","volume":"3","author":"L Wang","year":"2021","unstructured":"Wang L, Wang H, Wang Z, et al. Interpretation of healthy diet campaign in healthy China initiative 2019\u20132030. China CDC Wkly. 2021;3(16):346\u20139.","journal-title":"China CDC Wkly"},{"issue":"1","key":"2863_CR68","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1186\/s12889-022-14959-z","volume":"22","author":"Y Jian","year":"2022","unstructured":"Jian Y, Zhu D, Zhou D, et al. ARIMA model for predicting chronic kidney disease and estimating its economic burden in China. BMC Public Health. 2022;22(1):2456.","journal-title":"BMC Public Health"},{"issue":"1","key":"2863_CR69","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMc1602469","volume":"375","author":"L Zhang","year":"2016","unstructured":"Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China. N Engl J Med. 2016;375(1):905\u20136.","journal-title":"N Engl J Med"},{"issue":"6","key":"2863_CR70","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41581-018-0001-y","volume":"14","author":"HJ Anders","year":"2018","unstructured":"Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14(6):361\u201377.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2863_CR71","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/ckj\/sfac218","volume":"16","author":"Y Li","year":"2023","unstructured":"Li Y, Ning Y, Shen B, et al. Temporal trends in prevalence and mortality for chronic kidney disease in China from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019. Clin Kidney J. 2023;16(2):312\u201321.","journal-title":"Clin Kidney J"},{"issue":"7","key":"2863_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157323","volume":"11","author":"BO Yarnoff","year":"2016","unstructured":"Yarnoff BO, Hoerger TJ, Simpson SA, et al. The cost-effectiveness of anemia treatment for persons with chronic kidney disease. PLoS ONE. 2016;11(7):e0157323.","journal-title":"PLoS ONE"},{"issue":"12","key":"2863_CR73","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2215\/CJN.03790322","volume":"17","author":"P McEwan","year":"2022","unstructured":"McEwan P, Darlington O, Miller R, et al. Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022;17(12):1730\u201341.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2863_CR74","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3111\/13696998.2011.644407","volume":"15","author":"H Naci","year":"2012","unstructured":"Naci H, de Lissovoy G, Hollenbeak C, et al. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis. J Med Econ. 2012;15(2):293\u2013304.","journal-title":"J Med Econ"},{"key":"2863_CR75","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.vhri.2014.01.001","volume":"3","author":"T Thaweethamcharoen","year":"2014","unstructured":"Thaweethamcharoen T, Sakulbumrungsil R, Nopmaneejumruslers C, Vasuvattakul S. Cost-utility analysis of erythropoietin for anemia treatment in thai end-stage renal disease patients with hemodialysis. Value Health Reg Issues. 2014;3:44\u20139.","journal-title":"Value Health Reg Issues"},{"key":"2863_CR76","unstructured":"National Healthcare Security Administration. Homepage 2023. http:\/\/www.nhsa.gov.cn\/. Accessed 22 Apr 2024."},{"key":"2863_CR77","unstructured":"Institute for Health Metrics and Evaluation (IHME). IHME Client Services: Our Data 2023. https:\/\/www.ihmeclientservices.org\/ihmedata.html. Accessed 22 Apr 2024."},{"issue":"3","key":"2863_CR78","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/svn-2020-000457","volume":"5","author":"YJ Wang","year":"2020","unstructured":"Wang YJ, Li ZX, Gu HQ, et al. China stroke statistics 2019: a report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations. Stroke Vasc Neurol. 2020;5(3):211\u201339.","journal-title":"Stroke Vasc Neurol"}],"updated-by":[{"DOI":"10.1007\/s12325-024-03012-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02863-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02863-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02863-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T08:19:15Z","timestamp":1731658755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02863-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":78,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2863"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02863-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12325-024-03012-7","asserted-by":"object"}]},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"8 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-024-03012-7","URL":"https:\/\/doi.org\/10.1007\/s12325-024-03012-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jiaqi Yao, Yuzheng Zhang, Chalet Zhang, Juan Jose Garcia Sanchez, Claudia Cabrera, Dunming Xiao, Naveen Rao and Susan Grandy are employees of AstraZeneca at the time of the study. Yiqing Wu is an employee of Fibrogen. Laura Webber, Alex Martin and Joshua Card-Gowers are employees of HealthLumen Limited which has received research support from AstraZeneca. Lise Retat was an employee at HealthLumen Limited at the time of the study, and is now employed at AstraZeneca. Zuo Li and Jianwei Xuan have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Therefore, ethics approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}